top of page

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

69.31 -3.14 (-4.33%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,388,089
Open	72.13
Bid (Size)	69.28 (2,800)
Ask (Size)	69.39 (100)
Prev. Close	72.45
Today's Range	68.55 - 72.19
52wk Range	47.22 - 88.31
Shares Outstanding	95,640,600
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗

September 11, 2026

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market...

Via Benzinga

If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today ↗

August 28, 2026

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market...

Via Benzinga

Performance

YTD	+12.3%	+12.3%
1 Month	-8.6%	-8.6%
3 Month	-2.9%	-2.9%
6 Month	+13.9%	+13.9%
1 Year	+40.2%	+40.2%

More News

Cytokinetics’ Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM ↗

August 28, 2026

Via MarketBeat

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 ↗

August 22, 2026

Via The Motley Fool

Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch ↗

August 06, 2026

Via Chartmill

Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗

April 23, 2026

Via Chartmill

Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗

February 24, 2026

Via Chartmill

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Cytokinetics Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today ↗

August 05, 2026

Via Benzinga

Prediction: U.S. Small-Cap Stocks Will Beat Large Caps for 10 Years ↗

July 21, 2026

Via The Motley Fool

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% ↗

July 14, 2026

Via The Motley Fool

Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗

May 22, 2026

Via MarketBeat

Cytokinetics (CYTK) Q1 2026 Earnings Transcript ↗

May 05, 2026

Via The Motley Fool

Wondering what's happening in today's pre-market session? ↗

May 05, 2026

Via Chartmill

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

Via The Motley Fool

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

Via The Motley Fool

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

Via The Motley Fool

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Via The Motley Fool

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

Via The Motley Fool

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

Via The Motley Fool

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗

March 09, 2026

Via The Motley Fool

Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗

February 24, 2026

Via The Motley Fool

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

Via MarketMinute

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Via MarketMinute

Frequently Asked Questions

Is Cytokinetics, Incorporated - Common Stock publicly traded?

Yes, Cytokinetics, Incorporated - Common Stock is publicly traded.

What exchange does Cytokinetics, Incorporated - Common Stock trade on?

Cytokinetics, Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cytokinetics, Incorporated - Common Stock?

The ticker symbol for Cytokinetics, Incorporated - Common Stock is CYTK on the Nasdaq Stock Market

What is the current price of Cytokinetics, Incorporated - Common Stock?

The current price of Cytokinetics, Incorporated - Common Stock is 69.31

When was Cytokinetics, Incorporated - Common Stock last traded?

The last trade of Cytokinetics, Incorporated - Common Stock was at 09/15/26 04:00 PM ET

What is the market capitalization of Cytokinetics, Incorporated - Common Stock?

The market capitalization of Cytokinetics, Incorporated - Common Stock is 6.63B

How many shares of Cytokinetics, Incorporated - Common Stock are outstanding?

Cytokinetics, Incorporated - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

bottom of page